Omalizumab treatment in a child with severe asthma and multiple steroid-induced morbidities.
Caroline
C
Rizk
Alicia
A
Ring
Stephanie
S
Santucci
Ian
I
MacLusky
Jacob
J
Karsh
William H
WH
Yang
D000309:Adrenal Insufficiency / Q000209:etiology / Q000276:immunology / Q000628:therapy; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D001416:Back Pain / Q000209:etiology / Q000276:immunology / Q000628:therapy; D002648:Child; D006801:Humans; D008297:Male; D000069444:Omalizumab; D011241:Prednisone / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D011241:Prednisone